NCT04592003 French Colorectal ESD Cohort in Experts Centers
| NCT ID | NCT04592003 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Limoges |
| Condition | Cancer Colorectal |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2020-01-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2020-01-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR. Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures. A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions. The aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.
Eligibility Criteria
Inclusion Criteria: All patients addressed for a colorectal ESD Exclusion Criteria: Opposition notified in the context of a non-opposition form after reading the information notice
Contact & Investigator
Jérémie Jacques, Pr
PRINCIPAL INVESTIGATOR
Service d'Hépato-Gastro-Entérologie et Nutrition du CHU de LIMOGES
Frequently Asked Questions
Who can join the NCT04592003 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Colorectal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04592003 currently recruiting?
Yes, NCT04592003 is actively recruiting participants. Contact the research team at jeremie.jacques@chu-limoges.fr for enrollment information.
Where is the NCT04592003 trial being conducted?
This trial is being conducted at Amiens, France, Angers, France, Besançon, France, Bordeaux, France and 11 additional locations.
Who is sponsoring the NCT04592003 clinical trial?
NCT04592003 is sponsored by University Hospital, Limoges. The principal investigator is Jérémie Jacques, Pr at Service d'Hépato-Gastro-Entérologie et Nutrition du CHU de LIMOGES. The trial plans to enroll 1,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.